Literature DB >> 16953213

The second international meeting on allogeneic transplantation in solid tumors.

M Bregni1, N T Ueno, R Childs.   

Abstract

In October 2005, the second international meeting on allogeneic transplantation in solid tumors was convened in Stresa (Italy). The aim of this second meeting was to share clinical experiences of allografting in solid tumors, to discuss preclinical data on the mechanisms of graft-versus-tumor (GVT) effect, and to review methods for more efficacious transplant approaches. On the first day, the most recent results in cancer immunotherapy were reviewed; head-to head comparisons of clinical results achieved by standard therapy and by allografting in renal, breast, and ovarian cancer were presented. On the second day, GVT mechanisms and preclinical models were examined; anecdotal reports of a GVT effect in sarcoma, pancreatic cancer, prostate cancer, colorectal cancer and lung cancer were presented; new strategies for optimizing transplant outcome were discussed, including patient selection, tumor debulking, auto-allo approaches, selective T-cell depletion, targeting with monoclonal antibodies, use of killer cell immunoglobulin-like receptor-ligand mismatched natural killer cells. In conclusion, allografting in solid tumors is feasible with limited toxicities and transplant-related mortality; a GVT effect has been documented in many different solid tumors; targeting of the immune response to the tumor by new strategies and identification of the target antigen(s) of the GVT effect are promising areas of research.

Entities:  

Mesh:

Year:  2006        PMID: 16953213     DOI: 10.1038/sj.bmt.1705479

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

Review 1.  Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.

Authors:  Brenda M Sandmaier; Stephen Mackinnon; Richard W Childs
Journal:  Biol Blood Marrow Transplant       Date:  2007-01       Impact factor: 5.742

2.  Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells.

Authors:  Yoshiyuki Takahashi; Nanae Harashima; Sachiko Kajigaya; Hisayuki Yokoyama; Elena Cherkasova; J Philip McCoy; Ken-Ichi Hanada; Othon Mena; Roger Kurlander; Abdul Tawab; Tawab Abdul; Ramaprasad Srinivasan; Andreas Lundqvist; Elizabeth Malinzak; Nancy Geller; Michael I Lerman; Richard W Childs
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

3.  The combined administration of partially HLA-matched irradiated allogeneic lymphocytes and thalidomide in advanced renal-cell carcinoma: a case report.

Authors:  Qiang Chen; Rong-Bo Lin; Yun-Bin Ye; Nan-Feng Fan; Zeng-Qing Guo; Zhi-Feng Zhou; Xiao-Jie Wang; Min-Shui Chen; Shu-Pin Chen; Jie-Yu Li
Journal:  Med Oncol       Date:  2009-06-16       Impact factor: 3.064

4.  The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells.

Authors:  Heather J Symons; Moshe Y Levy; Jie Wang; Xiaotao Zhou; Gang Zhou; Sarah E Cohen; Leo Luznik; Hyam I Levitsky; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2008-05       Impact factor: 5.742

Review 5.  The Principles of Engineering Immune Cells to Treat Cancer.

Authors:  Wendell A Lim; Carl H June
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 6.  Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer.

Authors:  Nuri Karadurmus; Ugur Sahin; Bilgin Bahadir Basgoz; Fikret Arpaci; Taner Demirer
Journal:  World J Transplant       Date:  2016-12-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.